Yeo Eun Kim MD, Presenter: Nothing to Disclose

Mi-Suk Park MD, Abstract Co-Author: Nothing to Disclose

Youn Mi Son, Abstract Co-Author: Nothing to Disclose

Hon Soul Kim MD, PhD, Abstract Co-Author: Nothing to Disclose

Myeong-Jin Kim MD, PhD, Abstract Co-Author: Nothing to Disclose

Ki Whang Kim MD, Abstract Co-Author: Nothing to Disclose

To prospectively investigate whether tumor perfusion parameters of DCE-MRI are correlated with progression-free survival (PFS) in patients with liver metastases from CRC treated with bevacizumab.

29 patients with liver metastases from CRC received bevacizumab therapy. DCE-MRI (Ktrans, iAUC60) was performed at baseline and on 3 and 14 days after treatment. The changes in perfusion parameters between baseline and the day 3, 14 were calculated. A vascular response was defined by a 30% or greater decrease in perfusion parameters after treatment. PFS estimated by Kaplan-Meier method was compared between the patients with more than 30% decrease in perfusion parameters and the patients without it by using the log-rank test.

The mean PFS was longer for patients with more than 30% decrease in Ktrans from baseline to the day 3 (15.4 months) than the patients without it (6.9 months), with marginal significance (p=0.067). The mean PFS was longer for patients with more than 30% decrease in iAUC60 from baseline to the day 3 (15.4 months) than the patients without it, (6.6 months) with marginal significance (p=0.053). The change of perfusion parameters between baseline and the day 14 did not influence the PFS.

Conclusion: DCE-MRI can be used to quantify perfusion changes as early as 3 day after bevacizumab treatment in patients with liver metastases from CRC. More than 30% decrease of tumor perfusion at 3 days is predictive for good therapeutic response in patients with liver metastases from CRC.

DCE-MRI is predictive for good therapeutic response in patients with liver metastases from CRC.

Kim, Y, Park, M, Son, Y, Kim, H, Kim, M, Kim, K, Role of Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) in Early Prediction of Response to Bevacizumab Therapy in Liver Metastases of Colorectal Cancer (CRC): A Preliminary Result.  Radiological Society of North America 2012 Scientific Assembly and Annual Meeting, November 25 - November 30, 2012 ,Chicago IL. http://archive.rsna.org/2012/12034958.html